Clinical Outcomes of Post-placental Insertion of Cupper T380A and Multiload 375 Contraceptive Devices During Cesarean Section

November 20, 2022 updated by: Mahmoud Ahmed Abdelmawgoud, Sohag University
Clinical outcomes of post-placental insertion of Cupper T380A and Multiload 375 contraceptive devices during cesarean section

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

An intrauterine device (IUD) is considered one of the most effective, highly convenient and cheap methods of contraception[1]. IUD has been endorsed as a first-line contraceptive choice by the American College of Obstetricians and Gynecologists [2]. However, many complications have been reported with its use, such as irregular bleeding, expulsion, pelvic pain, and unexpected pregnancy.

Furthermore, extrauterine migration of IUD may result in damage to adjacent organs, bowel injury or even death [3]. Well-designed studies have elucidated that uterine perforation is expected in 0.2 to 3.6 per 1000 IUD insertions [4]. In addition, some case reports have shown IUD displacement into the sigmoid colon and lower urinary tract [5-8].

Nearly, fifty percent of malpositioned IUDs are asymptomatic and usually undetected for many years. Taking into consideration the possible risk of extrauterine migration and its dangerous sequelas, follow-up examinations are advised for all women after IUD insertion [9].

One of the safe, trusted and most convenient strategies to avoid new unwanted pregnancies is immediate postpartum IUD placement, within 10 minutes of delivery of the placenta [10]. However, expulsion rates are higher after immediate postpartum IUD insertions in comparison to delayed postpartum insertions (4-6 weeks postpartum)[11-13] Ultrasonographic assessment is considered the standard tool for confirming the position of an IUD.

2) Aim of the study The aim of the current study is to compare two types of intrauterine devices, namely Cu T380A IUD and Multiload 375 IUD, inserted immediately post placental, as regard to expulsion rates, safety, efficacy, side effects, and complications.

3) Subjects and Methods

1) Study type: A randomized comparative clinical trial 4) Methods: This study is a clinical trial that will include all patients fulfilling the eligibility criteria and presented to the emergency unit of the department of Obstetrics and Gynecology at Sohag University hospital (Egyptian tertiary referral hospital) who are requesting immediate postpartum contraception between November 2022 and September 2023. The attending physician will explain the nature of the study and all patients included will be asked to sign an informed consent. Participants were randomly allocated through a computer-generated list into two groups. In the first group Cu-T380A (Pregna International Ltd) will be inserted while in the second group Multiload 375 (Pregna International Ltd, Mumbai, India) will be inserted, Researchers and participants will not be masked to the type of IUCD inserted.

IUCDs will be inserted high at the fundus through the lower uterine segment incision immediately after delivery of the placenta using the cylinder provided within the sterile packaging; the IUCD pushing rod will not be used. Before placement in the uterine cavity, both IUCD strings were lengthened using 10 cm of Vicryl sutures (polyglactin 910) number 0 which will then threaded through the cylinder to appear at the other end. Following insertion adjacent to the fundus, the cylinder will be gradually moved downwards across the threads, passed through the cervix, and removed vaginally after delivery [14], This technique ensures that the threads are located within the vagina immediately after the operation and prevents their entanglement within the cervical canal or uterine cavity[14]. The uterine incision will then be closed in two layers.

Transabdominal US will be done to all patients before discharge to ensure adequate position of the IUD and then Women will be requested to attend follow-up appointment at 6 weeks after delivery, gynecological examination in addition to transvaginal sonography will be done to measure top-fundal distance that reflects the position of the IUD. The participants were instructed to report the pattern of bleeding during the puerperium, the number of sanitary pads used per day, the presence of blood clots, missed periods, fever, or vaginal discharge. They were shown how to find the threads and informed to urgently seek medical care if they could not feel the threads. During the puerperium, the Vicryl suture knot appeared below the cervix; the threads were shortened to a length of 2 cm from the cervix. Transabdominal and transvaginal 2D ultrasonography will be used to evaluate IUCD position in each visit. Complete expulsion was recorded when the longitudinal arm of the IUCD was partially or totally inside the cervix or vagina. Partial expulsion or displacement was recorded when the IUCD was more than 10 mm away from the fundus but still totally within the uterine cavity [15]. Women with severe PID who did not respond to treatment and/or had severe menorrhagia were candidates for IUCD discontinuation and were prescribed another contraception method if required.

5) Statistical analysis: Data will be expressed as mean ± standard deviation (SD), unless stated otherwise. Chi-squared test will be used to compare categorical variables and Student's t-test to compare continuous variables. A p-value of <0.05 will be considered statistically significant. STATA v14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) and MedCalc programs and will be used for data analysis.

6) Study results and impact: The current study may prove or disprove the benefits versus the risks of intrapartum insertion of different types of IUCDs.

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt
        • Sohag University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

All patients admitted for delivery at obstetric and gynecology emergency unit of sohag university hospital which is a tertiary center at sohag city in egypt who requested postpartum contraception, were invited to participate in the study

Description

Inclusion Criteria:

-(1) All patients admitted for delivery at our department who requested postpartum contraception, were invited to participate in the study.

(2) Age (18-45)

Exclusion Criteria:

  • (1) Intrauterine infection at time of delivery (chorioamnionitis) (2) postpartum hemorrhage (3) Uterine anomalies (distorted uterine cavity) (4) History of previous IUD expulsion (5) Anemic patients with hemoglobin< 10gm/dl (6) pre-labor rupture of membranes for more than 18 hours (7) Placenta previa.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
A
post-placental insertion of CU T380A IUD during CS
Device: CU T380A IUD
post-placental insertion of intrauterine contraceptive device
Other Names:
  • CU T380A
B
post-placental insertion of multiload 375 IUD during CS
Device: multiload 375 IUD
post-placental insertion of intrauterine contraceptive device
Other Names:
  • multiload 375

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The expulsion rate of Multiload IUCD versus CopperT380A after post-placental insertion
Time Frame: 6 weeks
The expulsion rate of Multiload IUCD versus CopperT380A after post-placental insertion
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Uterine bleeding
Time Frame: 6 weeks
number of bleeding days
6 weeks
Uterine bleeding
Time Frame: 6 weeks
pattern of bleeding
6 weeks
Uterine bleeding
Time Frame: 6 weeks
presence of blood clots
6 weeks
PID
Time Frame: 6 weeks
pesence of fever or vaginal discharge
6 weeks
perforation
Time Frame: 6 weeks
presence of abdominal pain
6 weeks
pregnancy on top of IUCD
Time Frame: 6 weeks
missed periods , or pregnancy
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 22, 2022

Primary Completion (Anticipated)

September 1, 2023

Study Completion (Anticipated)

September 1, 2023

Study Registration Dates

First Submitted

October 21, 2022

First Submitted That Met QC Criteria

November 20, 2022

First Posted (Actual)

November 22, 2022

Study Record Updates

Last Update Posted (Actual)

November 22, 2022

Last Update Submitted That Met QC Criteria

November 20, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • soh-Med-22-11-03

Drug and device information, study documents

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe